B2B

Innatoss promotes improvements in the diagnosis of infectious diseases. To achieve this, we collaborate with medical practices, companies and international research organizations.

As a laboratory, we support clinical practices with our expertise and innovative tests. New certified tests, which are already available abroad, will be introduced to the Netherlands as soon as possible. For example, innovative products are introduced in Europe by Innatoss.

Periodic screening services for Lyme disease for companies

For companies whose employees have a higher risk of contracting Lyme Disease (e.g. employees who work in forestry), Innatoss performs periodic screening services focused on Lyme’s disease. This is an annual screening of employees in order to detect new infections in time. In this way, we aim to prevent long-term sick leave caused by Lyme disease.

International research

Innatoss is also involved in international research as CRO. For example, we are working on the development of the new Q fever vaccine. This is the Q-VAXcelarate project led by the Massachusetts General Hospital (US) and funded by the US Department of Defense. Work conducted at Innatoss includes a broad T-cell antigenicity screen in a regional Q-fever exposed cohort, as well as cytometry-based profiling of Coxiella-induced responses in selected individuals.

In the field of Lyme disease, Innatoss collaborates with the Medical University of Vienna (Austria). DIARECT (Germany), and Npk Design (NL) on the development of a cell-mediated immunity test for Borrelia. The consortium is funded by the European commission under the Horizon2020 program (www.id-lyme.eu).

Technical capabilities and clinical trial competence

Innatoss Laboratories is located at the Pivot Park in the Netherlands; a state-of-the-art Life Sciences Center. Thanks to the Pivot Park, Innatoss has access to robotic equipment for high-throughput screening.

Innatoss has its own BSL-1 laboratory facilities, including standard equipment for the analysis of serological and cellular immune responses. This includes, among others,:

• biosafety cabinets
• ELISA readers
• washers and autoblots
• gel electrophoresis
• western-blotting equipment for protein analysis.

T-cell responses are analyzed using a company-owned Quickplex (MesoScale Discovery) and ELISPOT reader (AID), as well as the Pivot Park owned flow cytometer (FACS Canto II).

For clinical studies involving humans, Innatoss works with the medical ethical review board METC Brabant. The IRB is registered with the DHS under number IORG0008513. Innatoss has Federal Wide Assurance from the Office for Human Research Protections (FWA00023118). Dr. Marlies van Lent is registered in the Netherlands as clinical research scientist (BROK register) and Eva Hartman, MD, a BIG-registered general practitioner, is associated with the company as medical advisor.